What is it about?

Mesenchymal stem cell (MSC)-based therapy has been applicated in clinical settings for decades. Our review summarized the use of MSCs for ARDS patients in preclinical and clinical studies and discussed the application of MSCs for patients with COVID-19 and the related important issues.

Featured Image

Why is it important?

Our review showed that mesenchymal stem cell (MSC)-based therapy has been widely used for treatment of ARDS patients. Thus, according to the similar mechanism, MSC-based therapy should be a promising approach for COVID-19 patients.

Perspectives

Writing this article is to increase the understanding of COVID-19 treatments for peers and people in other fields, as the outbreak of COVID-19 has brought trauma to many people's life more or less. I hope this article will help you to have a deeper understanding of this novel infectious disease.

Jing Xiong
Children's Hospital of Chongqing Medical University

Read the Original

This page is a summary of: Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential, Current Stem Cell Research & Therapy, February 2021, Bentham Science Publishers, DOI: 10.2174/1574888x15666200601152832.
You can read the full text:

Read

Resources

Contributors

The following have contributed to this page